Amber Luong, MD, PhD, professor and vice chair for academic affairs in the Department of Otorhinolaryngology at McGovern Medical School at UTHealth Houston, was an invited moderator and presenter at the 7th Congress of European ORL-HNS held in Dublin June 15-19, 2024. The conference is the largest ENT gathering in Europe, with more than 3,000 attendees. This year’s event was held in the award-winning Convention Centre Dublin and featured an extensive scientific program, including 16 parallel sessions that addressed the scientific needs of otorhinolaryngologists, related specialists, and allied health care professionals.
Dr. Luong moderated a panel discussion entitled “Incorporating Endotypes into My Practice,” which featured speakers Dr. Kasper Aanæs, associate professor in the Department of Clinical Medicine at the University of Copenhagen; Dr. Eugenio De Corso, medical director of the Department of NeuroScience, Sensory Organs, and Chest at the Fondazione Policlinico Universitario Agostino Gemelli in Rome; and Dr. Valerie Hox, assistant professor of otorhinolaryngology at Cliniques universitaires Saint-Luc in Brussels.
She also made an invited presentation entitled “Type 2 or Not Type 2: That’s the Question,” elaborating on her research seeking to understand the molecular cause of chronic rhinosinusitis (CRS) to develop better treatment options. “Severe rhinosinusitis is a debilitating disease with a significant impact on patient quality of life. Through research, treatment options have expanded from steroids and surgery to including biologics that target specific molecules that drive CRS,” she says. “With the advent of biologics, our treatment goals have gone beyond controlling disease to aspiring to remission, which for the patient means no nasal congestion, runny nose, or loss of sense of smell. If we can push remission out to five years, we’re approaching the concept of cure, which always is our goal as clinicians and researchers.”